Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression

Overview of attention for article published in Blood, January 2015

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (92nd percentile)
High Attention Score compared to outputs of the same age and source (96th percentile)

So far, Altmetric has seen 1 news story.

Summary EPZM's solid tumor data was recently released. On close inspection, the data is remarkably weak.

This page shows the most recent news stories that mention this research output.

Click here to find out how to access more activity.